跳至內容

地屈孕酮

維基百科,自由的百科全書
地屈孕酮
臨床資料
商品名英語Drug nomenclatureDuphaston, others
其他名稱Isopregnenone; Dehydroprogesterone; Didrogesteron; 6-Dehydroretroprogesterone; 9β,10α-Pregna-4,6-diene-3,20-dione; NSC-92336[1][2]
AHFS/Drugs.com國際藥品名稱
給藥途徑By mouth
藥物類別英語Drug classProgestin; Progestogen
ATC碼
法律規範狀態
法律規範
  • 處方藥(-only)
藥物動力學數據
生物利用度28%[3]
血漿蛋白結合率? (probably to albumin)[3][4]
藥物代謝Hepatic: AKR1C1, AKR1C3, CYP3A4[7][5]
代謝產物20α-DHD (exclusively via AKR1C1 and AKRC13)[5]
生物半衰期Parent: 5–7 hours[6]
Metabolite: 14–17 hours[6]
排泄途徑Urine
識別資訊
  • (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
CAS號152-62-5  checkY
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.005.280 編輯維基數據鏈接
化學資訊
化學式C21H28O2
摩爾質量312.446 g/mol
3D模型(JSmol英語JSmol
熔點144 °C(291 °F)
沸點463 °C(865 °F)
水溶性Insoluble mg/mL (20 °C)
  • O=C4\C=C3\C=C/[C@@H]1[C@@H](CC[C@@]2([C@@H](C(=O)C)CC[C@@H]12)C)[C@]3(C)CC4
  • InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1 checkY
  • Key:JGMOKGBVKVMRFX-HQZYFCCVSA-N checkY

地屈孕酮(英語:Dydrogesterone,縮寫DYD,商品名為Duphaston等)是一種黃體製劑藥物,用於治療一系列疾病,包括妊娠期的習慣性流產黃體期缺陷(LPD)造成的功能失調性子宮出血不孕經痛子宮內膜異位症,繼發性閉經月經周期紊亂經前綜合症,是激素替代療法的選用藥物之一[4],通常由口服給藥[4]

參考文獻

  1. ^ J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 474– [2019-06-09]. ISBN 978-1-4757-2085-3. (原始內容存檔於2020-08-03). 
  2. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000: 378–. ISBN 978-3-88763-075-1. 
  3. ^ 3.0 3.1 ((Howard JA Carp, MB, BS, FRCOG)). Progestogens in Obstetrics and Gynecology. Springer. 9 April 2015: 33, 38. ISBN 978-3-319-14385-9.  溫哥華格式錯誤 (幫助)
  4. ^ 4.0 4.1 4.2 Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005,. 8 Suppl 1: 3–63. PMID 16112947. doi:10.1080/13697130500148875. 
  5. ^ 5.0 5.1 Beranič, N.; Gobec, S.; Rižner, T. Lanišnik. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chemico-Biological Interactions. 2011, 191 (1–3): 227–233. ISSN 0009-2797. PMID 21182831. doi:10.1016/j.cbi.2010.12.012. 
  6. ^ 6.0 6.1 Bińkowska, Małgorzata; Woroń, Jarosław. Progestogens in menopausal hormone therapy. Menopausal Review. 2015, 14 (2): 134–143. ISSN 1643-8876. PMC 4498031可免費查閱. PMID 26327902. doi:10.5114/pm.2015.52154. 
  7. ^ Olbrich, Matthias; Weigl, Kevin; Kahler, Elke; Mihara, Katsuhiro. Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes. Xenobiotica. 2016, 46 (10): 868–874. ISSN 0049-8254. PMID 26796435. doi:10.3109/00498254.2015.1134852.